Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A W Schneider

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Der Urologe. Ausg. A|June 16, 2019
[The affiliated physician in Germany: the end of a cross-sector form of care?]A W Schneider
Der Urologe. Ausg. A|March 1, 1990
[Tumor markers and prognostic parameters in urinary bladder cancer]A W Schneider, H Huland
Der Urologe. Ausg. A|July 25, 2014
[The demographic development in Germany : challenge and chances for urology]A W Schneider, J Fichtner
Der Urologe. Ausg. A|September 1, 1989
[Quantitative immunocytology as a marker for indications and follow-up of recurrence prevention of superficial urinary bladder cancers]A W Schneider, E Huland, H Huland
The Journal of Urology|September 1, 1990
Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxisE Huland, H Huland, A W Schneider
Health & Social Work|December 5, 2000
Suggestions to social workers for surviving in managed careA W Schneider, K Hyer, M Luptak
Journal of Molecular Evolution|May 25, 2002
The evolution of gymnosperms redrawn by phytochrome genes: the Gnetatae appear at the base of the gymnospermsMarion Schmidt, Hansjörg A W Schneider-Poetsch
Deutsche Medizinische Wochenschrift (1946)|February 28, 1992
[Thrombocytopenia in digitoxin poisoning]A W Schneider, H J Gilfrich, L Fechler
Medizinische Klinik (Munich, Germany : 1983)|June 15, 1996
[Ticlopidine-induced pancytopenia: therapy of agranulocytosis with granulocyte colony stimulating factor]A W Schneider, L Fechler, H J Gilfrich
Progress in Clinical and Biological Research|January 1, 1990
Recombinant alpha-2 or gamma interferon in the treatment of metastatic renal cell carcinoma: results of two phase II/III trialsU Otto, A W Schneider, S Conrad, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Der Urologe. Ausg. A|June 16, 2019
[The affiliated physician in Germany: the end of a cross-sector form of care?]A W Schneider
Der Urologe. Ausg. A|March 1, 1990
[Tumor markers and prognostic parameters in urinary bladder cancer]A W Schneider, H Huland
Der Urologe. Ausg. A|July 25, 2014
[The demographic development in Germany : challenge and chances for urology]A W Schneider, J Fichtner
Der Urologe. Ausg. A|September 1, 1989
[Quantitative immunocytology as a marker for indications and follow-up of recurrence prevention of superficial urinary bladder cancers]A W Schneider, E Huland, H Huland
The Journal of Urology|September 1, 1990
Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxisE Huland, H Huland, A W Schneider
Health & Social Work|December 5, 2000
Suggestions to social workers for surviving in managed careA W Schneider, K Hyer, M Luptak
Journal of Molecular Evolution|May 25, 2002
The evolution of gymnosperms redrawn by phytochrome genes: the Gnetatae appear at the base of the gymnospermsMarion Schmidt, Hansjörg A W Schneider-Poetsch
Deutsche Medizinische Wochenschrift (1946)|February 28, 1992
[Thrombocytopenia in digitoxin poisoning]A W Schneider, H J Gilfrich, L Fechler
Medizinische Klinik (Munich, Germany : 1983)|June 15, 1996
[Ticlopidine-induced pancytopenia: therapy of agranulocytosis with granulocyte colony stimulating factor]A W Schneider, L Fechler, H J Gilfrich
Progress in Clinical and Biological Research|January 1, 1990
Recombinant alpha-2 or gamma interferon in the treatment of metastatic renal cell carcinoma: results of two phase II/III trialsU Otto, A W Schneider, S Conrad, et al.
Pageof 3